 <h1>Topiramate Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of topiramate include:</b> anxiety, ataxia, confusion, diarrhea, diplopia, dizziness, drowsiness, dysphasia, fatigue, lack of concentration, memory impairment, nausea, nervousness, paresthesia, psychomotor disturbance, speech disturbance, depression, visual disturbance, weight loss, dysgeusia, mood changes, and anorexia. <b>Other side effects include:</b> arthralgia, and asthenia.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to topiramate: oral capsule, oral capsule extended release, oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, topiramate may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking topiramate:</p><p>
<i>More common</i>
</p><ul>
<li>Blurred vision</li>
<li>burning, prickling, or tingling sensations</li>
<li>clumsiness or unsteadiness</li>
<li>confusion</li>
<li>continuous, uncontrolled back-and-forth or rolling eye movements</li>
<li>dizziness</li>
<li>double vision</li>
<li>drowsiness</li>
<li>eye redness or pain</li>
<li>generalized slowing of mental and physical activity</li>
<li>increased eye pressure</li>
<li>memory problems</li>
<li>menstrual changes</li>
<li>menstrual pain</li>
<li>nervousness</li>
<li>speech or language problems</li>
<li>trouble in concentrating or paying attention</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Aggression</li>
<li>agitation</li>
<li>chest pain</li>
<li>chills</li>
<li>discouragement</li>
<li>feeling sad or empty</li>
<li>fever</li>
<li>irritability</li>
<li>lack of feeling or emotion</li>
<li>lessening of sensations or perception</li>
<li>loss of appetite</li>
<li>loss of interest or pleasure </li>
<li>red, irritated, or bleeding gums</li>
<li>sore throat</li>
<li>stomach pain</li>
<li>trouble sleeping</li>
<li>weight loss</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Blood in the urine</li>
<li>difficult or painful urination</li>
<li>frequent urination</li>
<li>hearing loss</li>
<li>itching, skin rash</li>
<li>loss of bladder control</li>
<li>lower back or side pain</li>
<li>nosebleeds</li>
<li>pale skin</li>
<li>ringing or buzzing in the ears</li>
<li>swelling</li>
<li>trouble breathing</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blistering, peeling, or loosening of the skin</li>
<li>bloating</li>
<li>clay-colored stools</li>
<li>constipation</li>
<li>cough</li>
<li>diarrhea</li>
<li>increased rate of breathing</li>
<li>joint or muscle pain</li>
<li>pain or tenderness in the upper stomach</li>
<li>red skin lesions, often with a purple center</li>
<li>sores, ulcers, or white spots in the mouth or on the lips</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Get emergency help immediately if any of the following symptoms of overdose occur while taking topiramate:</i>
</p><p>
<i>Symptoms of overdose</i>
</p><ul>
<li>Decreased awareness or responsiveness</li>
<li>dizziness, fainting, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>severe sleepiness</li>
<li>unusual drowsiness, dullness, or feeling of sluggishness</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of topiramate may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Breast pain in women</li>
<li>tremors</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Back pain</li>
<li>constipation</li>
<li>feeling of warmth</li>
<li>heartburn</li>
<li>increased sweating</li>
<li>leg pain</li>
<li>redness of the face, neck, arms, and occasionally, upper chest</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Decrease in sexual performance or desire</li>
</ul><p>
<!-- end oral capsule, oral capsule extended release, oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to topiramate: oral capsule, oral capsule extended release, oral tablet</i></p><h3>Cardiovascular</h3><p><b>Uncommon</b> (0.1% to 1%): Bradycardia, sinus bradycardia, palpitations, hypotension, orthostatic hypotension, flushing, hot flush</p>
<p><b>Rare</b> (less than 0.1%): Raynaud's phenomenon<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Alopecia, rash, pruritus</p>
<p><b>Uncommon</b> (0.1% to 1%): Anhidrosis, hypoesthesia facial, urticaria, erythema, pruritus generalized, rash macular, skin discoloration, dermatitis allergic, swelling face </p>
<p><b>Rare</b> (less than 0.1%): Stevens-Johnson syndrome, erythema multiforme, skin odor abnormal, periorbital edema, urticaria localized</p>
<p><b>Frequency not reported</b>: Toxic epidermal necrolysis, oligohidrosis</p>
<p><b>Postmarketing reports</b>: Bullous skin reactions, pemphigus<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea, diarrhea</p>
<p><b>Common</b> (1% to 10%): Vomiting, constipation, abdominal pain upper, dyspepsia, abdominal pain, dry mouth, stomach discomfort, paresthesia oral, gastritis, abdominal discomfort</p>
<p><b>Uncommon</b> (0.1% to 1%): Pancreatitis, flatulence, gastroesophageal reflux disease, abdominal pain lower, hypoesthesia oral, gingival bleeding, abdominal distension, epigastric discomfort, abdominal tenderness, salivary hypersecretion, oral pain, breath odor, glossodynia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Uncommon</b> (0.1% to 1%): Erectile dysfunction, sexual dysfunction, renal calculus, intermenstrual bleeding, leucorrhoea, menorrhagia, vaginitis, amenorrhea, urinary tract infections, micturition frequency, urinary incontinence, dysuria</p>
<p><b>Postmarketing reports</b>: Kidney stones, nephrocalcinosis<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Anemia, epistaxis</p>
<p><b>Uncommon</b> (0.1% to 1%): Leucopenia, thrombocytopenia lymphadenopathy, white blood cell count decreased, eosinophilia</p>
<p><b>Rare</b> (less than 0.1%): Neutropenia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Rare</b> (less than 0.1%): Hepatitis, hepatic failure, increase in liver enzymes</p>
<p><b>Postmarketing reports</b>: Hepatic failure including fatalities<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity</p>
<p><b>Frequency not reported</b>: Allergic edema, conjunctival edema<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Nasopharyngitis</p>
<p><b>Frequency not reported</b>: Genital moniliasis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Weight decreased</p>
<p><b>Common</b> (1% to 10%): Anorexia, decreased appetite, weight increased</p>
<p><b>Uncommon</b> (0.1% to 1%): Metabolic acidosis, hypokalemia, increased appetite, polydipsia</p>
<p><b>Rare</b> (less than 0.1%): Acidosis hyperchloremic, blood bicarbonate decreased</p>
<p><b>Postmarketing reports</b>: Hyperammonemia with and without encephalopathy<sup>[Ref]</sup></p><p>Metabolic Acidosis: </p>
<p>Generally, topiramate-induced metabolic acidosis occurs early in treatment; however, it can occur any time.  Average decreases of serum bicarbonate of 4 mEq/L have been observed in adults receiving 400 mg/day and pediatrics receiving approximately 6 mg/kg/day.  Values below 10 mEq/L have been rarely reported.  In adult trials for adjunctive treatment of epilepsy, persistent serum bicarbonate decreases to less than 20 meq/L were reported in 32% of patients receiving 400 mg/day versus 1% of placebo-treated patients.  In pediatric trials, adjunctive therapy yielded persistent decreases in serum bicarbonate of 67% for doses of approximately 6 mg/kg/day and 10% for placebo.  In monotherapy trials for patients 6 to 15 years, the incidence of persistent decreases in serum bicarbonate was 9% for 50 mg per day and 25% for 400 mg per day.  In adult migraine trials, persistent decreases in serum bicarbonate occurred in 44%, 39%, 23%, and 7% of patients receiving 200 mg/day, 100 mg/day, 50 mg/day, and placebo, respectively.  In adolescent migraine trials, this was 77%, 27%, 30%, and 9% for those receiving 200 mg/day, 100 mg/day, 50 mg/day, and placebo, respectively.</p>
<p></p>
<p>Hyperammonemia:</p>
<p>The incidence of hyperammonemia (above the upper limit of normal) for adolescent patients receiving this drug for migraine prophylaxis was 26%, 14%, and 9% for doses of 100 mg, 50, mg, or placebo, respectively.  Hyperammonemia with and without encephalopathy has been reported in the post-marketing period.  Hyperammonemia appears to be more common when used concomitantly with valproic acid.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia, muscle spasms, myalgia, muscle twitching, muscular weakness, musculoskeletal chest pain</p>
<p><b>Uncommon</b> (0.1% to 1%): Joint swelling, musculoskeletal stiffness, flank pain, muscle fatigue</p>
<p><b>Rare</b> (less than 0.1%): Limb discomfort<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Paraesthesia, somnolence, dizziness</p>
<p><b>Common</b> (1% to 10%): Disturbance in attention, memory impairment, amnesia, cognitive disorder, mental impairment, psychomotor skills impaired, convulsion, coordination abnormal, tremor, lethargy, hypethesia, nystagmus, dysgeusia, balance disorder, dysarthria, intention tremor, sedation</p>
<p><b>Uncommon</b> (0.1% to 1%): Depressed level of consciousness, grand mal convulsion, visual field defect, complex partial seizures, speech disorder, psychomotor hyperactivity, syncope, sensory disturbance, drooling, hypersomnia, aphasia, repetitive speech, hypokinesia, dyskinesia, dizziness postural, poor quality sleep, burning sensation, sensory loss, parosmia, cerebellar syndrome, dysesthesia, hypogeusia, stupor, clumsiness, aura, ageusia, dysgraphia, dysphasia, neuropathy peripheral, presyncope, dystonia, formication</p>
<p><b>Rare</b> (less than 0.1%): Apraxia, circadian rhythm sleep disorder, hyperesthesia, hyposmia, anosmia, essential tremor, akinesia, unresponsive to stimuli<sup>[Ref]</sup></p><p>Most CNS adverse reactions can be classified into 3 categories: cognitive-related dysfunction (e.g.  confusion psychomotor slowing, difficulty with concentration/attention, difficulty with memory, speech, or language problems, particularly word-finding difficulties); psychiatric/behavioral disturbances (e.g.  depression or mood problems); and somnolence or fatigue.  Most were mild to moderate in severity and frequently occurred in isolation.  Rapid titration rate and higher initial dose was associated with a higher occurrence.<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Vision blurred, diplopia, visual disturbance</p>
<p><b>Uncommon</b> (0.1% to 1%): Visual acuity reduced, scotoma, myopia, abnormal sensation in eye, dry eye, photophobia, blepharospasm, lacrimation increased, photopsia, mydriasis, presbyopia</p>
<p><b>Rare</b> (less than 0.1%): Blindness unilateral, blindness transient, glaucoma, accommodation disorder, altered visual depth perception, scintillating scotoma, eyelid edema, night blindness, amblyopia</p>
<p><b>Frequency not reported</b>: Angle closure glaucoma, maculopathy, eye movement disorder<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue</p>
<p><b>Common</b> (1% to 10%): Vertigo, tinnitus, ear pain pyrexia, asthenia, irritability, gait disturbance, feeling abnormal, malaise</p>
<p><b>Uncommon</b> (0.1% to 1%): Deafness, deafness unilateral, deafness neurosensory, ear discomfort, hearing impaired, hyperthermia, thirst, influenza like illness, sluggishness, peripheral coldness, feeling drunk, feeling jittery, tandem gait test abnormal</p>
<p><b>Rare</b> (less than 0.1%): Face edema, calcinosis, learning disability</p>
<p><b>Frequency not reported</b>: Hypothermia, hyperthermia (associated with oligohidrosis)<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Somnolence (15%), memory loss (10%), depression</p>
<p><b>Common</b> (1% to 10%): Depression, difficulty with concentration/attention, anxiety psychomotor slowing, altered mood, confusion, cognitive difficulty, bradyphrenia, decreased libido, expressive language disorder, disorientation, aggression, aggression, anger, abnormal behavior</p>
<p><b>Uncommon</b> (0.1% to 1%): Suicidal ideation, suicide attempt, hallucination, psychotic disorder, hallucination auditory, hallucination visual, apathy, lack of spontaneous speech, sleep disorder, affect lability, restlessness, crying, dysphemia, euphoria, paranoia, perseveration, panic attack, tearfulness, reading disorder, flat affect, thinking abnormal, listlessness, middle insomnia, distractibility, early morning awakening, panic reaction, elevated mood </p>
<p><b>Rare</b> (less than 0.1%): Mania, panic disorder, feelings of despair, hypomania<sup>[Ref]</sup></p><p>Antiepileptic drugs increased the risk of suicidal thoughts or behaviors when taken for any indication.  Pooled analyses of 199 placebo-controlled clinical trials of 11 different antiepileptic drugs showed patients on antiepileptics had approximately twice the risk compared to placebo.  In these trials (median duration 12 weeks; most less than 24 weeks), the estimated incidence rate of suicidal behavior or ideation was 0.43% compared to 0.24% which represents an increase of approximately 1 case for every 530 patients treated.<sup>[Ref]</sup></p><h3>Renal</h3><p>In clinical trials, 1.5% of adult patients receiving this drug developed kidney stones (approximately 2 to 4 times more than expected).  The incidence was higher in men.  Kidney stone have been reported in pediatric patients taking this drug for epilepsy or migraine.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Nephrolithiasis, pollakiuria, dysuria</p>
<p><b>Uncommon</b> (0.1% to 1%): Calculus urinary, urinary incontinence, hematuria, incontinence, micturition urgency, renal colic, renal pain</p>
<p><b>Rare</b> (less than 0.1%): Calculus ureteric, renal tubular acidosis<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Bronchitis, rhinitis, dyspnea, epistaxis, nasal congestion, rhinorrhea, cough</p>
<p><b>Uncommon</b> (0.1% to 1%): Dyspnea exertional, paranasal sinus hypersecretion, dysphonia<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Topiramate (topiramate)." Cipla USA Inc., Miami, FL. </p><p id="ref_2">2. "Product Information. Qudexy XR Sprinkle (topiramate)." Upsher-Smith Laboratories Inc, Minneapolis, MN. </p><p id="ref_3">3. "Product Information. Trokendi XR (topiramate)." Supernus Pharmaceuticals Inc, Rockville, MD. </p><p id="ref_4">4. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_5">5. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>Does this drug cause weight loss?</li>
<li>When is the best time of day to take Trokendi XR?</li>
<li>What is it used to treat?</li>
<li>Are Topamax and Trokendi XR the same thing?</li>
<li>How does Trokendi XR help with weight loss?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about topiramate</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Support Group</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>1127 Reviews</li>
<li>Drug class: carbonic anhydrase inhibitor anticonvulsants</li>
<li>FDA Alerts (3)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Topiramate &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Topamax, Trokendi XR, Qudexy XR, Topamax Sprinkle, Topiragen</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +5 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Bipolar Disorder</li>
<li>Diabetic Peripheral Neuropathy</li>
<li>Borderline Personality Disorder</li>
<li>Bulimia</li>
<li data-more-config-id="list-data-resources-conditions">... +11 more</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to topiramate: oral capsule, oral capsule extended release, oral tablet</i></p><h3>Cardiovascular</h3><p><b>Uncommon</b> (0.1% to 1%): Bradycardia, sinus bradycardia, palpitations, hypotension, orthostatic hypotension, flushing, hot flush</p><p><b>Rare</b> (less than 0.1%): Raynaud's phenomenon<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Alopecia, rash, pruritus</p><p><b>Uncommon</b> (0.1% to 1%): Anhidrosis, hypoesthesia facial, urticaria, erythema, pruritus generalized, rash macular, skin discoloration, dermatitis allergic, swelling face </p><p><b>Rare</b> (less than 0.1%): Stevens-Johnson syndrome, erythema multiforme, skin odor abnormal, periorbital edema, urticaria localized</p><p><b>Frequency not reported</b>: Toxic epidermal necrolysis, oligohidrosis</p><p><b>Postmarketing reports</b>: Bullous skin reactions, pemphigus<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea, diarrhea</p><p><b>Common</b> (1% to 10%): Vomiting, constipation, abdominal pain upper, dyspepsia, abdominal pain, dry mouth, stomach discomfort, paresthesia oral, gastritis, abdominal discomfort</p><p><b>Uncommon</b> (0.1% to 1%): Pancreatitis, flatulence, gastroesophageal reflux disease, abdominal pain lower, hypoesthesia oral, gingival bleeding, abdominal distension, epigastric discomfort, abdominal tenderness, salivary hypersecretion, oral pain, breath odor, glossodynia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Uncommon</b> (0.1% to 1%): Erectile dysfunction, sexual dysfunction, renal calculus, intermenstrual bleeding, leucorrhoea, menorrhagia, vaginitis, amenorrhea, urinary tract infections, micturition frequency, urinary incontinence, dysuria</p><p><b>Postmarketing reports</b>: Kidney stones, nephrocalcinosis<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Anemia, epistaxis</p><p><b>Uncommon</b> (0.1% to 1%): Leucopenia, thrombocytopenia lymphadenopathy, white blood cell count decreased, eosinophilia</p><p><b>Rare</b> (less than 0.1%): Neutropenia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Rare</b> (less than 0.1%): Hepatitis, hepatic failure, increase in liver enzymes</p><p><b>Postmarketing reports</b>: Hepatic failure including fatalities<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity</p><p><b>Frequency not reported</b>: Allergic edema, conjunctival edema<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Nasopharyngitis</p><p><b>Frequency not reported</b>: Genital moniliasis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Weight decreased</p><p><b>Common</b> (1% to 10%): Anorexia, decreased appetite, weight increased</p><p><b>Uncommon</b> (0.1% to 1%): Metabolic acidosis, hypokalemia, increased appetite, polydipsia</p><p><b>Rare</b> (less than 0.1%): Acidosis hyperchloremic, blood bicarbonate decreased</p><p><b>Postmarketing reports</b>: Hyperammonemia with and without encephalopathy<sup>[Ref]</sup></p><p>Metabolic Acidosis: </p><p>Generally, topiramate-induced metabolic acidosis occurs early in treatment; however, it can occur any time.  Average decreases of serum bicarbonate of 4 mEq/L have been observed in adults receiving 400 mg/day and pediatrics receiving approximately 6 mg/kg/day.  Values below 10 mEq/L have been rarely reported.  In adult trials for adjunctive treatment of epilepsy, persistent serum bicarbonate decreases to less than 20 meq/L were reported in 32% of patients receiving 400 mg/day versus 1% of placebo-treated patients.  In pediatric trials, adjunctive therapy yielded persistent decreases in serum bicarbonate of 67% for doses of approximately 6 mg/kg/day and 10% for placebo.  In monotherapy trials for patients 6 to 15 years, the incidence of persistent decreases in serum bicarbonate was 9% for 50 mg per day and 25% for 400 mg per day.  In adult migraine trials, persistent decreases in serum bicarbonate occurred in 44%, 39%, 23%, and 7% of patients receiving 200 mg/day, 100 mg/day, 50 mg/day, and placebo, respectively.  In adolescent migraine trials, this was 77%, 27%, 30%, and 9% for those receiving 200 mg/day, 100 mg/day, 50 mg/day, and placebo, respectively.</p><p></p><p>Hyperammonemia:</p><p>The incidence of hyperammonemia (above the upper limit of normal) for adolescent patients receiving this drug for migraine prophylaxis was 26%, 14%, and 9% for doses of 100 mg, 50, mg, or placebo, respectively.  Hyperammonemia with and without encephalopathy has been reported in the post-marketing period.  Hyperammonemia appears to be more common when used concomitantly with valproic acid.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia, muscle spasms, myalgia, muscle twitching, muscular weakness, musculoskeletal chest pain</p><p><b>Uncommon</b> (0.1% to 1%): Joint swelling, musculoskeletal stiffness, flank pain, muscle fatigue</p><p><b>Rare</b> (less than 0.1%): Limb discomfort<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Paraesthesia, somnolence, dizziness</p><p><b>Common</b> (1% to 10%): Disturbance in attention, memory impairment, amnesia, cognitive disorder, mental impairment, psychomotor skills impaired, convulsion, coordination abnormal, tremor, lethargy, hypethesia, nystagmus, dysgeusia, balance disorder, dysarthria, intention tremor, sedation</p><p><b>Uncommon</b> (0.1% to 1%): Depressed level of consciousness, grand mal convulsion, visual field defect, complex partial seizures, speech disorder, psychomotor hyperactivity, syncope, sensory disturbance, drooling, hypersomnia, aphasia, repetitive speech, hypokinesia, dyskinesia, dizziness postural, poor quality sleep, burning sensation, sensory loss, parosmia, cerebellar syndrome, dysesthesia, hypogeusia, stupor, clumsiness, aura, ageusia, dysgraphia, dysphasia, neuropathy peripheral, presyncope, dystonia, formication</p><p><b>Rare</b> (less than 0.1%): Apraxia, circadian rhythm sleep disorder, hyperesthesia, hyposmia, anosmia, essential tremor, akinesia, unresponsive to stimuli<sup>[Ref]</sup></p><p>Most CNS adverse reactions can be classified into 3 categories: cognitive-related dysfunction (e.g.  confusion psychomotor slowing, difficulty with concentration/attention, difficulty with memory, speech, or language problems, particularly word-finding difficulties); psychiatric/behavioral disturbances (e.g.  depression or mood problems); and somnolence or fatigue.  Most were mild to moderate in severity and frequently occurred in isolation.  Rapid titration rate and higher initial dose was associated with a higher occurrence.<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Vision blurred, diplopia, visual disturbance</p><p><b>Uncommon</b> (0.1% to 1%): Visual acuity reduced, scotoma, myopia, abnormal sensation in eye, dry eye, photophobia, blepharospasm, lacrimation increased, photopsia, mydriasis, presbyopia</p><p><b>Rare</b> (less than 0.1%): Blindness unilateral, blindness transient, glaucoma, accommodation disorder, altered visual depth perception, scintillating scotoma, eyelid edema, night blindness, amblyopia</p><p><b>Frequency not reported</b>: Angle closure glaucoma, maculopathy, eye movement disorder<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue</p><p><b>Common</b> (1% to 10%): Vertigo, tinnitus, ear pain pyrexia, asthenia, irritability, gait disturbance, feeling abnormal, malaise</p><p><b>Uncommon</b> (0.1% to 1%): Deafness, deafness unilateral, deafness neurosensory, ear discomfort, hearing impaired, hyperthermia, thirst, influenza like illness, sluggishness, peripheral coldness, feeling drunk, feeling jittery, tandem gait test abnormal</p><p><b>Rare</b> (less than 0.1%): Face edema, calcinosis, learning disability</p><p><b>Frequency not reported</b>: Hypothermia, hyperthermia (associated with oligohidrosis)<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Somnolence (15%), memory loss (10%), depression</p><p><b>Common</b> (1% to 10%): Depression, difficulty with concentration/attention, anxiety psychomotor slowing, altered mood, confusion, cognitive difficulty, bradyphrenia, decreased libido, expressive language disorder, disorientation, aggression, aggression, anger, abnormal behavior</p><p><b>Uncommon</b> (0.1% to 1%): Suicidal ideation, suicide attempt, hallucination, psychotic disorder, hallucination auditory, hallucination visual, apathy, lack of spontaneous speech, sleep disorder, affect lability, restlessness, crying, dysphemia, euphoria, paranoia, perseveration, panic attack, tearfulness, reading disorder, flat affect, thinking abnormal, listlessness, middle insomnia, distractibility, early morning awakening, panic reaction, elevated mood </p><p><b>Rare</b> (less than 0.1%): Mania, panic disorder, feelings of despair, hypomania<sup>[Ref]</sup></p><p>Antiepileptic drugs increased the risk of suicidal thoughts or behaviors when taken for any indication.  Pooled analyses of 199 placebo-controlled clinical trials of 11 different antiepileptic drugs showed patients on antiepileptics had approximately twice the risk compared to placebo.  In these trials (median duration 12 weeks; most less than 24 weeks), the estimated incidence rate of suicidal behavior or ideation was 0.43% compared to 0.24% which represents an increase of approximately 1 case for every 530 patients treated.<sup>[Ref]</sup></p><h3>Renal</h3><p>In clinical trials, 1.5% of adult patients receiving this drug developed kidney stones (approximately 2 to 4 times more than expected).  The incidence was higher in men.  Kidney stone have been reported in pediatric patients taking this drug for epilepsy or migraine.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Nephrolithiasis, pollakiuria, dysuria</p><p><b>Uncommon</b> (0.1% to 1%): Calculus urinary, urinary incontinence, hematuria, incontinence, micturition urgency, renal colic, renal pain</p><p><b>Rare</b> (less than 0.1%): Calculus ureteric, renal tubular acidosis<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Bronchitis, rhinitis, dyspnea, epistaxis, nasal congestion, rhinorrhea, cough</p><p><b>Uncommon</b> (0.1% to 1%): Dyspnea exertional, paranasal sinus hypersecretion, dysphonia<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Topiramate (topiramate)." Cipla USA Inc., Miami, FL. </p><p id="ref_2">2. "Product Information. Qudexy XR Sprinkle (topiramate)." Upsher-Smith Laboratories Inc, Minneapolis, MN. </p><p id="ref_3">3. "Product Information. Trokendi XR (topiramate)." Supernus Pharmaceuticals Inc, Rockville, MD. </p><p id="ref_4">4. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_5">5. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>Does this drug cause weight loss?</li>
<li>When is the best time of day to take Trokendi XR?</li>
<li>What is it used to treat?</li>
<li>Are Topamax and Trokendi XR the same thing?</li>
<li>How does Trokendi XR help with weight loss?</li>
</ul><h2>More about topiramate</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Support Group</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>1127 Reviews</li>
<li>Drug class: carbonic anhydrase inhibitor anticonvulsants</li>
<li>FDA Alerts (3)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Topiramate &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +5 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Bipolar Disorder</li>
<li>Diabetic Peripheral Neuropathy</li>
<li>Borderline Personality Disorder</li>
<li>Bulimia</li>
<li data-more-config-id="list-data-resources-conditions">... +11 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>